RxDoctor Payments Data

Maria Husain, MD

Ophthalmology · San Antonio, TXNPI 1851611024

Payments from drug & device makers

$4,359in general payments, 2019–2025

Across 67 payments — averaging $65.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Enterprises LLC$3K
  • AbbVie$589
  • Johnson & Johnson Surgical Vision, Inc.$180
  • Sun Pharmaceutical Industries Inc.$151
  • Coherus Oncology, Inc.$133
  • Mallinckrodt Hospital Products Inc.$100
  • plus $593 from 16 others

What the payments were for

  • Consulting fees$2,47557%
  • Speaking & faculty fees$190%
  • Food & beverage$1,76540%
  • Education$1002%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,359 in reported general payments places this provider in the 70th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$181,949
Medicare patients
603
Services billed
1,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine50$66,833
XiidraLifitegrast17$28,447
LumiganBimatoprost25$13,322
ProlensaBromfenac Sodium26$9,064
Cyclosporine16$8,918
SimbrinzaBrinzolamide/Brimonidine Tart18$8,832
Restasis MultidoseCyclosporine13$8,415
Prednisolone Acetate125$3,985
Timolol Maleate69$3,732
Latanoprost303$3,495
Dorzolamide-TimololDorzolamide/Timolol/Pf17$2,620
MoxifloxacinMoxifloxacin Hcl87$2,221
Bromfenac Sodium11$2,107
Fluorometholone28$2,078
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat133$1,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose$589$88,56988 claims
Bausch & Lomb Americas Inc.Xiidra$81$28,44717 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$14$9,06426 claims
AlconSimbrinza$64$8,83218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →